With the recent approval of Nivolumab for second-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC), immune checkpoint inhibitors are entering the standard of care for lung cancer. Other immune checkpoint inhibitors are under evaluation, both in resectable and non-resectable NSCLC. In order to refine our use of these molecules, comprehensive data on the immune contexture of NSCLC are needed. Moreover,a blood marker of this contexture would allow physicians to monitor the immune status of their patient's tumor and though to evaluate the rightful place of immunotherapy in the multimodal treatment of NSCLC. No such blood marker has been validated so far. The LYMPHOLUNG study investigate the concordance between blood and intratumoral counts of immune cells in resectable stage I to IIIA NSCLC. By the use of 30-marker cytometry, a precise immune profile of NSCLC will be depicted. The prognostic value of the circulating and intra-tumoral T regulator over total lymphocytes ratio for 2-year recurrence-free survival will also be addressed.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Enrollment
22
blood drawn
Rouen University Hospital
Rouen, France
Level of expression of the T regulator over total lymphocytes count ratio in the blood
Time frame: Day 1
Level of expression of the T regulator over total lymphocytes count ratio into the tumor
Time frame: Day 1
Number of cell population counts as blood markers for the corresponding population in the tumor
Time frame: Day 1
Number of patient alive 2 years after resection
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.